US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Praxis Precision Medicines, Inc. - Common Stock
(NQ:
PRAX
)
295.51
+8.60 (+3.00%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 07, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
May 04, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
April 14, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines (NASDAQ:PRAX) Reports Q4 2025 Results Amid Key Regulatory Milestones
↗
February 19, 2026
Via
Chartmill
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
April 13, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
April 06, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
March 30, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
↗
March 22, 2026
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.
Via
The Motley Fool
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
↗
March 18, 2026
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Via
The Motley Fool
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
↗
March 16, 2026
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
Via
The Motley Fool
Topics
Regulatory Compliance
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
↗
March 16, 2026
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
↗
March 16, 2026
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
↗
March 16, 2026
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
Via
The Motley Fool
Topics
Regulatory Compliance
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
↗
March 15, 2026
This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.
Via
The Motley Fool
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
↗
March 13, 2026
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
↗
March 13, 2026
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Via
The Motley Fool
Topics
Regulatory Compliance
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
↗
March 13, 2026
Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Via
The Motley Fool
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
↗
March 13, 2026
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.
Via
The Motley Fool
Topics
Regulatory Compliance
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know
↗
March 13, 2026
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
↗
March 13, 2026
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.
Via
The Motley Fool
Topics
Regulatory Compliance
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
↗
February 23, 2026
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.
Via
The Motley Fool
Topics
Regulatory Compliance
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Via
The Motley Fool
Topics
Regulatory Compliance
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock
↗
February 20, 2026
Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of...
Via
Stocktwits
Praxis Medicines Q4 2025 Earnings Call Transcript
↗
February 19, 2026
Praxis Medicines Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
